GENENTECH, INC for GENENTECH INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report (this page) | Apr 20, 2011 | $1,248,359 | Replaced |
| 1st Quarter - Amendment | Sep 21, 2012 | $1,258,359 | Yes |
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Food Industry (safety, labeling, etc.) FOO
monitor and report and food safety and supply chain issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assoc. Director Government Affairs |
| DARIN GARDNER | Director Government Affairs |
| EVAN MORRIS | VP Government Affairs |
Taxation/Internal Revenue Code TAX
General tax issues and tax extenders; Monitoring proposals on U.S. tax treatment of foreign corporations;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Director VP Government Affairs |
| EVAN MORRIS | VP Government Affairs |
Trade (domestic/foreign) TRD
Monitor issues related to export rules and regulations, international patent issues,; matters and other international issues impacting biotech and pharmaceuticals
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assoc. Director Government Affairs |
| DARIN GARDNER | Assoc. Director Government Affairs |
| EVAN MORRIS | VP Government Affairs |
Health Issues HCR
Avastin, Lucentis,FDA Appropriations; Issues concerning clincial trials. General health care reform (Patient Protection and Affordable Care Act). Congressional oversight issues; Legislation on public health preparedness and response to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels; FDA approval and enforcement issues; Presciption Drug User Fee Act (PDUFA), Avastin -use in breast cancer treatment, dry macular degeneration; S.726/HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act; HR 1548 - Pathway for Biosimilars Act, General support for Genentech products; HR1/1473 health care funding: FY 12 Labor HHS Appropriations legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assoc. Director Government Affairs |
| DARIN GARDNER | Director Government Affairs |
| ANNA GRIFFIN | Director Government Affairs |
| ELI KOGAN | Assoc. Director Affairs |
| EVAN MORRIS | VP Government Affairs |
| KATHERINE RAAB | Director Government Affairs |
Medicare/Medicaid MMM
Implementation of HR 1: Medicare Prescription Drug and Modernization Act of 2003, Issues relating to PDUFA, stimulus. Issues relating to comparative effectiveness an CMS converage of FDA approved therapies. Issues related to the PPS rule involving stroke guidelines; Monitor implementation of Medicare pharmaceutical converage and reimbursement provisions of PL 111-148-Patient Protection and Affordable Care Act and PL 111-152 - Health Care and Education Reconciliation Act; Advocacy related to ensuring access to necessary medicines; PHA Advocacy related to ensurig access to necessary medicines
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assoc. Government Affairs |
| DARIN GARDNER | Director Government Affairs |
| ANNA GRIFFIN | Director Government Affairs |
| EVAN MORRIS | VP Government Affairs |
Budget/Appropriations BUD
Issues related to pandemic preparedness and macular degeneration; HCR: Issues related to health care reform; FY11 FY12 Labor, HHS and Education Appropriation related to preparedness for pandemic influenza, HIV/AIDS programs and HCV screening, care and treatment. Implementation of HR 2346, S.1054 FY09 Supplemental Appropriations related to preparedness for pandemic influenza
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Director Government Affairs |
| EVAN MORRIS | VP Government Affairs |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.